A statement that a peptide is stable is incomplete unless it identifies the material, conditions and period being discussed. Stability can differ between a bulk substance and a finished formulation, and the container can be part of the relevant evidence.

ICH Q1A(R2) describes stability studies for new drug substances and products. The framework links observed quality changes over time with defined conditions. It is a useful benchmark for asking what evidence supports a storage claim, while its specific regulatory applicability requires expert assessment. EMA ICH Q1A R2 stability guideline

Identify what was measured

A stability study should use measurements capable of detecting relevant changes. Appearance alone may not reveal chemical degradation, and a single identity test may not quantify a changing impurity. The analytical question should match the potential failure mode.

The record should also identify whether the container remained unopened and whether the tested formulation matches the supplied product. Data from one format should not be transferred to another merely because the active ingredient has the same name.

Distinguish dates with different meanings

An expiry date, retest date and shipping estimate communicate different things. None should be inferred from another. A retest date calls for a defined quality assessment; it is not simply a promise that the material remains suitable indefinitely.

For AXON readers, the useful procurement question is not “How long do peptides last?” but “What stability evidence supports this exact material under these stated conditions?” If the evidence is unavailable, say so and seek a qualified quality assessment. This article intentionally gives no universal storage temperature, preparation method or post-opening timetable. Such instructions require product-specific validated information, and they would not establish permission for human use.